Skip to main content
TipRanks
Go Ultimate75% OFF

MeVis Medical Solutions (M3V) AI Stock Analysis

3 Followers
DE:M3V

MeVis Medical Solutions

(XETRA:M3V)

Select Model
Rating:64Neutral
Price Target:EUR 21.50â–²(5.39% Upside)
Action:reiterated
Date:08/07/26

The score is held up by the **exceptionally strong balance sheet** and decent cash flow quality, but **declining revenue and margins** are the main drag. Weak technical momentum also weighs on the result, while valuation and dividend yield provide only limited support.

Positive Factors
Debt-free balance sheetZero total debt and stable equity materially reduce financial risk, preserve flexibility during weaker trading, and leave the company better positioned to fund operations or strategic investment without repayment or refinancing pressure.
Negative Factors
Multi-year revenue declineRevenue has declined for three consecutive annual reports, showing that the business has not recently converted its medical-imaging software position into sustained top-line expansion. Continued contraction could constrain operating leverage and reduce the resources available for growth initiatives.

MeVis Medical Solutions (M3V) vs. iShares MSCI Germany ETF (EWG)

-20%-15%-10%-5%0%5%10%15%20%DE:M3V-14.64%EWG+7.58%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
EUR 37.13M
Dividend Yield
4.66%
Average Volume (3M)
228
Price to Earnings (P/E)
26.8
Beta (1Y)
0.18
Revenue Growth
-6.92%
EPS Growth
-67.82%
Country
Germany
Employees
127
Sector
General
Sector Strength
55
Industry
Software - Application

MeVis Medical Solutions Business Overview & Revenue Model

Company Description

MeVis Medical Solutions AG develops software for recording, analyzing, and evaluating image data to manufacturers of medical devices, providers of medical IT platforms, and clinical end customers in the United States and Europe. The company provides...

MeVis Medical Solutions Financial Statement Overview

Summary

Strong balance sheet strength with **zero debt** and solid equity returns supports the score, but **declining revenue**, lower margins, and uneven cash flow keep it below the top range.

Income Statement

72Positive

Balance Sheet

95Very Positive

Cash Flow

68Positive
Financial statement breakdown
BreakdownTTMSep 2025Sep 2024Sep 2023Sep 2022Sep 2021
Income Statement
Total Revenue15.48M16.06M16.97M17.34M18.76M16.21M
Gross Profit3.13M15.69M16.48M7.00M18.02M15.78M
EBITDA791.01K3.43M4.82M5.17M7.97M4.77M
Net Income1.38M3.17M4.56M4.92M7.79M4.55M
Balance Sheet
Total Assets23.16M25.89M26.48M28.05M31.20M27.53M
Cash, Cash Equivalents and Short-Term Investments3.65M6.52M6.53M7.74M9.32M7.62M
Total Debt000000
Total Liabilities5.34M8.06M8.66M10.23M13.38M9.71M
Stockholders Equity17.83M17.83M17.83M17.83M17.83M17.83M
Cash Flow
Free Cash Flow03.74M2.84M5.77M4.72M9.08M
Operating Cash Flow03.88M3.15M5.85M4.86M9.13M
Investing Cash Flow0945.46K906.80K989.98K58.66K111.63K
Financing Cash Flow0-4.56M-4.92M-7.79M-4.55M-5.70M

MeVis Medical Solutions Technical Analysis

Technical Analysis SentimentNegative
Last Price20.40

Price Trends

50DMA21.68Negative
100DMA22.80Negative
200DMA23.17Negative

Market Momentum

MACD-0.45Negative
RSI45.38Neutral
STOCH85.30Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For DE:M3V, the sentiment is Negative. The current price of 20.40 is above the 20-day moving average (MA) of 20.27, below the 50-day MA of 21.68, and below the 200-day MA of 23.17, indicating a neutral trend. The MACD of -0.45 indicates Negative momentum. The RSI at 45.38 is Neutral, neither overbought nor oversold. The STOCH value of 85.30 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for DE:M3V.

MeVis Medical Solutions Peers Comparison

Overall Rating

UnderperformOutperform
Sector (55)

Financial Indicators

DE:M3V against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
DE:EUZDE:EUZ80OutperformEUR 930.47M17.0920.26%1.48%4.05%36.66%
DE:SHLDE:SHL77OutperformEUR 48.31B21.8711.72%2.31%1.09%3.52%
DE:DRW8DE:DRW870OutperformEUR 1.81B12.3510.20%2.66%5.06%40.18%
DE:M3VDE:M3V64NeutralEUR 37.13M26.847.77%4.66%-6.92%-67.82%
Sector *55Neutral$6.65B3.83-15.92%6.20%10.91%7.18%
DE:SBSDE:SBS54NeutralEUR 328.82M-7.75-18.69%2.22%――
DE:COPDE:COP53NeutralEUR 1.47B43.424.19%1.78%――

* General Sector Average

Performance Comparison

-20%0%20%40%DE:M3VDE:COPDE:DRW8DE:EUZDE:SBSDE:SHLDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
DE:M3V and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
DE:M3VMeVis Medical Solutions20.40-3.50-14.64%
DE:COPCompuGroup Medical27.854.5719.63%
DE:DRW8Draegerwerk AG & Co. KGaA (0MT8)83.2022.9037.97%
DE:EUZEckert & Ziegler Strahlen und Medizintechnik14.87-0.58-3.74%
DE:SBSSTRATEC Biomedical27.057.5738.89%
DE:SHLSiemens Healthineers43.302.907.18%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Aug 04, 2026